Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucerastat in treatment-naïve or pseudo-naïve adult men with Fabry disease
2026-525207-27-00Phase 3Authorised
- Sponsor
- Idorsia
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of lucerastat in Fabry disease (FD), sponsored by Idorsia. Primary endpoint: Change from baseline to Month 18 in kidney Gb3 BLISS score. Planned start Aug 2026; status: authorised.
02
Drugs
lucerastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2026-525207-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525207-27-00.